胰腺癌纳米递药系统靶向性设计研究进展

Advances in designation of targeting nanocarrier-drug delivery systems for pancreatic cancer

胰腺导管腺癌的肿瘤新生血管匮乏且基质丰富,限制了细胞毒性药物的递送效率,降低了治疗效果。纳米递送细胞毒性药物治疗胰腺癌有望克服其生物屏障,提高递药效率。而设计具有高效靶向胰腺癌细胞的纳米递药系统是克服上述生物屏障的关键。本文综述相关领域的最新进展,包括纳米递药系统的被动靶向设计、主动靶向设计及响应释放的靶向递药设计。

Pancreatic ductal adenocarcinoma is a kind of neoplasms with poor neovascularization and rich matrix,which limited the delivery of cytotoxic drugs to cancer cells.Nanocarriers delivery of cytotoxic drugs to treat pancreatic cancer would overcome those biological barriers,and promote drug delivery efficiency.The designation of high targeting of pancreatic cancer cells nanoparticles and smart drug delivery system have been the key factors to improve nanocarriers＇ drug delivery efficiency.Here,we report the latest advanced researches in this field,including passive targeting design,active targeting design and response to the release of drug delivery design.